Related Experiment Video

Updated: May 12, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Advantages of direct thrombin inhibition in high- and low-risk patients

Gregg W Stone1

  • 1Center for Interventional Vascular Therapy at Columbia University Medical Center, New York, New York, USA.

The Journal of Invasive Cardiology
|April 11, 2013
PubMed

Insights

Bivalirudin effectively prevents ischemic complications and minimizes bleeding in patients undergoing percutaneous coronary interventions (PCI). This anticoagulant offers improved outcomes as an alternative to heparin and glycoprotein IIb/IIIa inhibitors for various patient risk levels.

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Heparin and glycoprotein IIb/IIIa inhibitors are standard anticoagulants in percutaneous coronary interventions (PCI).
  • A need exists for anticoagulants that balance efficacy in preventing ischemic events with minimal bleeding risk across diverse patient populations.
  • Cost-effectiveness and streamlined care are crucial factors for ideal anticoagulant agents in PCI.

Purpose of the Study:

  • To evaluate bivalirudin as a potential replacement for heparin and glycoprotein IIb/IIIa inhibitors in interventional cardiology.
  • To assess the efficacy of bivalirudin in preventing ischemic complications and its safety profile regarding bleeding risk in PCI patients.
  • To explore the utility of bivalirudin in acute coronary syndromes (ACS) and acute myocardial infarction (AMI) settings.

Main Methods:

  • Review of pharmacokinetic properties of bivalirudin.
  • Analysis of clinical outcomes data comparing bivalirudin with heparin and glycoprotein IIb/IIIa inhibitors in PCI.
  • Consideration of patient risk stratification (low- and high-risk) in study populations.

Main Results:

  • Bivalirudin demonstrates favorable pharmacokinetic properties.
  • Studies show bivalirudin improves outcomes when used as an alternative to heparin and glycoprotein IIb/IIIa inhibitors during PCI.
  • Bivalirudin has been effective in both high- and low-risk patients undergoing urgent and elective PCI.

Conclusions:

  • Bivalirudin is a promising anticoagulant for interventional cardiology, offering improved outcomes and reduced bleeding risk in PCI.
  • Ongoing research is further investigating bivalirudin's role in managing acute coronary syndromes and acute myocardial infarction.
  • Bivalirudin presents a viable alternative to current anticoagulation strategies, potentially streamlining care and proving cost-effective.

More Related Videos

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...